Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colostrum-derived antibodies for C. difficile prevention
NCT00747071Phase 3Withdrawn
- Sponsor
- Hadassah Medical Organization
- Start
- Sep 2011
- Primary completion
- Nov 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of colostrum in Clostridium difficile infection (CDI) (2 arms), sponsored by Hadassah Medical Organization. Primary endpoints: Recurrence of active Clostridium difficile associated diarrhea at 60 days and New cases of Clostridium difficile associated diarrhea at 60 days. Planned start Sep 2011; status: withdrawn.
02
Drugs
colostrum
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT00747071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00747071.